Summit Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for serious unmet medical needs, with a leading oncology asset ivonescimab (a PD-1/VEGF bispecific antibody) in-licensed from Akeso for global development.
Company Info
Upcoming Milestones & Key Dates
FDA decision on ivonescimab BLA for 1L NSCLC
HARMONi-3 confirmatory trial interim readout
Clinical Development Pipeline
Recent News
Summit Therapeutics has withdrawn a planned $500M public offering, citing unfavorable market conditions. The move follows recent volatility in biotech equities and shifts investor expectations for the company's near-term funding strategy.
Summit Therapeutics pulled a planned $500M follow-on offering, citing unfavorable market conditions just weeks after presenting mixed Phase 3 ivonescimab data that triggered a sharp selloff in its shares.
Leadership Team
Careers & Job Openings